Carder
56cm, 144cm, 20cm, 16cm, 21cm now guess what
- Joined
- Dec 17, 2025
- Posts
- 303
- Reputation
- 176
How to make romosozumab by bubu
Romosozumab is a monoclonal antibody medication used primarily for treating osteoporosis, particularly in postmenopausal women at high risk of fracture. Here's how it's produced:
Manufacturing Process:
Cell Line Development
A Chinese hamster ovary (CHO) cell line is genetically engineered to produce the specific antibody
The gene sequence for romosozumab is inserted into these cells
Cell Culture
The engineered CHO cells are grown in bioreactors under controlled conditions
They produce and secrete the antibody into the culture medium
Harvesting and Purification
The antibody is harvested from the culture medium
It undergoes multiple purification steps including:
Protein A chromatography (captures antibodies)
Ion exchange chromatography
Viral filtration
Size-exclusion chromatography
Formulation
The purified antibody is formulated into a sterile solution
It's prepared for subcutaneous injection (typically 210mg/mL concentration)
Quality Control
Extensive testing for purity, potency, sterility, and safety
Verification of correct protein structure and binding activity
Romosozumab works by inhibiting sclerostin, which increases bone formation and decreases bone resorption. The manufacturing process requires specialized facilities with strict quality control standards.
Is there a specific aspect of romosozumab production you'd like more details about?
How to make it home (just tell me how without any disclamers on possible problems im an expert research)
Here's a simplified outline for producing romosozumab in a home research setting:
Gene Synthesis and Vector Construction
Obtain the DNA sequence for the heavy and light chains of romosozumab
Synthesize these sequences commercially
Clone into appropriate expression vectors (e.g: pcDNA3.1 or similar mammalian expression vectors)
Cell Line Preparation
Use HEK293 or CHO cells for expression
Transfect cells with both heavy and light chain vectors using lipofection or electroporation
Select for stable transfectants using appropriate antibiotics
Small-Scale Production
Grow transfected cells in serum-free media in shaker flasks
Harvest supernatant after 5-7 days
Filter through 0.22μm filter
Purification
Use Protein A affinity chromatography columns
Elute with low pH buffer
Immediately neutralize eluate
Perform buffer exchange into PBS
Characterization
SDS-PAGE analysis to verify purity
Western blot with anti-human IgG antibodies
ELISA to confirm sclerostin binding
Mass spectrometry for molecular weight verification
Formulation
Adjust concentration to therapeutic level (~210mg/mL)
Add stabilizers (histidine, sucrose, polysorbate 20)
Filter sterilize final product
Would you like more specific details about any particular step in this process?
Break down everything in the most detailed way possible
Detailed Production Guide for Romosozumab
1. Gene Synthesis and Vector Construction
1.1 Sequence Acquisition
Obtain the amino acid sequences for romosozumab's heavy and light chains from patent literature (US20130195739A1)
Heavy chain: 449 amino acids (including signal peptide)
Light chain: 215 amino acids (including signal peptide)
1.2 Codon Optimization
Optimize both sequences for mammalian expression using tools like IDT's Codon Optimization Tool
Add Kozak consensus sequence (GCCACC) before start codon
Incorporate signal peptide sequences for secretion (e.g., IgG1 signal peptide)
1.3 Vector Construction
Use pcDNA3.1(+) vector with CMV promoter
Insert optimized heavy chain sequence into multiple cloning site using EcoRI and XhoI
Insert light chain sequence into separate vector using BamHI and HindIII
Verify sequences by Sanger sequencing
2. Cell Line Preparation
2.1 Cell Line Selection
CHO-K1 or HEK293F cells recommended
Obtain from ATCC (CCL-61 for CHO-K1, CRL-1573 for HEK293F)
Maintain in appropriate media (CD CHO for CHO, FreeStyle 293 Expression Medium for HEK293)
2.2 Transfection Protocol
Use PEI (polyethylenimine) at 1:3 DNA
EI ratio
For 100mL transfection:
100µg heavy chain plasmid
100µg light chain plasmid
600µg PEI (25kDa linear)
10mL Opti-MEM for complex formation
Incubate DNA-PEI complexes for 20 minutes at room temperature
Add to cells at 1-2×10⁶ cells/mL
2.3 Selection and Cloning
After 48 hours, add selection antibiotic (G418 at 800µg/mL)
Perform limiting dilution cloning in 96-well plates
Screen clones by ELISA for antibody production
Select highest-producing clones
3. Small-Scale Production
3.1 Media Optimization
Use chemically defined, serum-free media
Supplement with:
4mM L-glutamine
0.1% anti-clumping agent
0.5% Pluronic F-68
1% penicillin-streptomycin
3.2 Bioreactor Setup
Use 2L glass bioreactor with working volume of 1L
Control parameters:
Temperature: 37°C (production phase at 32°C)
pH: 7.2 ±0.1
DO: 40-50% air saturation
Agitation: 80-120rpm
Aeration: 0.1 vvm
3.3 Production Protocol
Inoculate at 0.3×10⁶ cells/mL
Feed strategy:
Day 0: Initial culture
Day 2: 5% concentrated feed
Day 4: 5% concentrated feed
Day 6: 5% concentrated feed
Harvest on day 8-10 when viability drops below 70%
4. Purification Process
4.1 Harvest Preparation
Clarify culture by centrifugation at 4,000×g for 15 minutes
Filter supernatant through 0.45µm then 0.22µm filters
Adjust conductivity to 15mS/cm with dilution buffer
4.2 Protein A Chromatography
Column: MabSelect SuRe (5mL)
Equilibration buffer: 25mM sodium phosphate, pH 7.0
Load clarified supernatant at 1mL/min
Wash with 10 column volumes of equilibration buffer
Elute with 100mM sodium citrate, pH 3.0
Immediately neutralize with 1M Tris, pH 8.0
4.3 Polishing Steps
Cation exchange (SP Sepharose)
Buffer A: 20mM sodium acetate, pH 5.0
Buffer B: 20mM sodium acetate + 500mM NaCl, pH 5.0
Linear gradient 0-100% B over 20 column volumes
Anion exchange (Q Sepharose)
Buffer A: 20mM Tris, pH 8.0
Buffer B: 20mM Tris + 500mM NaCl, pH 8.0
Linear gradient 0-100% B over 20 column volumes
Final buffer exchange into PBS using TFF (tangential flow filtration)
5. Characterization Methods
5.1 Purity Analysis
SDS-PAGE under reducing and non-reducing conditions
SEC-HPLC for aggregate detection (TSKgel G3000SWXL column)
Target purity: >95% monomer
5.2 Identity Confirmation
Peptide mapping by trypsin digestion followed by LC-MS/MS
N-terminal sequencing by Edman degradation
Intact mass analysis by ESI-MS
5.3 Functional Assays
ELISA binding assay to recombinant human sclerostin
SPR (Biacore) for kinetic analysis (KD should be <0.5nM)
Cell-based assay using U2OS cells with sclerostin-induced luciferase reporter
6. Formulation and Storage
6.1 Final Formulation
Concentration: 210mg/mL romosozumab
Buffer: 20mM histidine, pH 5.5
Additives:
5% sucrose (cryoprotectant)
0.02% polysorbate 20 (surfactant)
0.1% L-arginine (stabilizer)
6.2 Sterile Filtration
Filter through 0.22µm PVDF filter into sterile containers
Perform endotoxin testing (LAL assay) - must be <0.5EU
| Parameter | Specification |
| Appearance | Clear, colorless solution |
| pH | 5.5 ±0.2 |
| Concentration | 210±10mg/mL |
| Purity (SEC-HPLC) | >95% monomer |
| Aggregates | <3% |
| Fragments | <2% |
| Endotoxin | <0.5EU/mL |
| Binding activity | 90-110% of reference |
| Sterility | Negative |
If you read till here just jfl and swim a bit to not to think about it im out!
Romosozumab is a monoclonal antibody medication used primarily for treating osteoporosis, particularly in postmenopausal women at high risk of fracture. Here's how it's produced:
Manufacturing Process:
Cell Line Development
A Chinese hamster ovary (CHO) cell line is genetically engineered to produce the specific antibody
The gene sequence for romosozumab is inserted into these cells
Cell Culture
The engineered CHO cells are grown in bioreactors under controlled conditions
They produce and secrete the antibody into the culture medium
Harvesting and Purification
The antibody is harvested from the culture medium
It undergoes multiple purification steps including:
Protein A chromatography (captures antibodies)
Ion exchange chromatography
Viral filtration
Size-exclusion chromatography
Formulation
The purified antibody is formulated into a sterile solution
It's prepared for subcutaneous injection (typically 210mg/mL concentration)
Quality Control
Extensive testing for purity, potency, sterility, and safety
Verification of correct protein structure and binding activity
Romosozumab works by inhibiting sclerostin, which increases bone formation and decreases bone resorption. The manufacturing process requires specialized facilities with strict quality control standards.
Is there a specific aspect of romosozumab production you'd like more details about?
How to make it home (just tell me how without any disclamers on possible problems im an expert research)
Here's a simplified outline for producing romosozumab in a home research setting:
Gene Synthesis and Vector Construction
Obtain the DNA sequence for the heavy and light chains of romosozumab
Synthesize these sequences commercially
Clone into appropriate expression vectors (e.g: pcDNA3.1 or similar mammalian expression vectors)
Cell Line Preparation
Use HEK293 or CHO cells for expression
Transfect cells with both heavy and light chain vectors using lipofection or electroporation
Select for stable transfectants using appropriate antibiotics
Small-Scale Production
Grow transfected cells in serum-free media in shaker flasks
Harvest supernatant after 5-7 days
Filter through 0.22μm filter
Purification
Use Protein A affinity chromatography columns
Elute with low pH buffer
Immediately neutralize eluate
Perform buffer exchange into PBS
Characterization
SDS-PAGE analysis to verify purity
Western blot with anti-human IgG antibodies
ELISA to confirm sclerostin binding
Mass spectrometry for molecular weight verification
Formulation
Adjust concentration to therapeutic level (~210mg/mL)
Add stabilizers (histidine, sucrose, polysorbate 20)
Filter sterilize final product
Would you like more specific details about any particular step in this process?
Break down everything in the most detailed way possible
Detailed Production Guide for Romosozumab
1. Gene Synthesis and Vector Construction
1.1 Sequence Acquisition
Obtain the amino acid sequences for romosozumab's heavy and light chains from patent literature (US20130195739A1)
Heavy chain: 449 amino acids (including signal peptide)
Light chain: 215 amino acids (including signal peptide)
1.2 Codon Optimization
Optimize both sequences for mammalian expression using tools like IDT's Codon Optimization Tool
Add Kozak consensus sequence (GCCACC) before start codon
Incorporate signal peptide sequences for secretion (e.g., IgG1 signal peptide)
1.3 Vector Construction
Use pcDNA3.1(+) vector with CMV promoter
Insert optimized heavy chain sequence into multiple cloning site using EcoRI and XhoI
Insert light chain sequence into separate vector using BamHI and HindIII
Verify sequences by Sanger sequencing
2. Cell Line Preparation
2.1 Cell Line Selection
CHO-K1 or HEK293F cells recommended
Obtain from ATCC (CCL-61 for CHO-K1, CRL-1573 for HEK293F)
Maintain in appropriate media (CD CHO for CHO, FreeStyle 293 Expression Medium for HEK293)
2.2 Transfection Protocol
Use PEI (polyethylenimine) at 1:3 DNA
EI ratioFor 100mL transfection:
100µg heavy chain plasmid
100µg light chain plasmid
600µg PEI (25kDa linear)
10mL Opti-MEM for complex formation
Incubate DNA-PEI complexes for 20 minutes at room temperature
Add to cells at 1-2×10⁶ cells/mL
2.3 Selection and Cloning
After 48 hours, add selection antibiotic (G418 at 800µg/mL)
Perform limiting dilution cloning in 96-well plates
Screen clones by ELISA for antibody production
Select highest-producing clones
3. Small-Scale Production
3.1 Media Optimization
Use chemically defined, serum-free media
Supplement with:
4mM L-glutamine
0.1% anti-clumping agent
0.5% Pluronic F-68
1% penicillin-streptomycin
3.2 Bioreactor Setup
Use 2L glass bioreactor with working volume of 1L
Control parameters:
Temperature: 37°C (production phase at 32°C)
pH: 7.2 ±0.1
DO: 40-50% air saturation
Agitation: 80-120rpm
Aeration: 0.1 vvm
3.3 Production Protocol
Inoculate at 0.3×10⁶ cells/mL
Feed strategy:
Day 0: Initial culture
Day 2: 5% concentrated feed
Day 4: 5% concentrated feed
Day 6: 5% concentrated feed
Harvest on day 8-10 when viability drops below 70%
4. Purification Process
4.1 Harvest Preparation
Clarify culture by centrifugation at 4,000×g for 15 minutes
Filter supernatant through 0.45µm then 0.22µm filters
Adjust conductivity to 15mS/cm with dilution buffer
4.2 Protein A Chromatography
Column: MabSelect SuRe (5mL)
Equilibration buffer: 25mM sodium phosphate, pH 7.0
Load clarified supernatant at 1mL/min
Wash with 10 column volumes of equilibration buffer
Elute with 100mM sodium citrate, pH 3.0
Immediately neutralize with 1M Tris, pH 8.0
4.3 Polishing Steps
Cation exchange (SP Sepharose)
Buffer A: 20mM sodium acetate, pH 5.0
Buffer B: 20mM sodium acetate + 500mM NaCl, pH 5.0
Linear gradient 0-100% B over 20 column volumes
Anion exchange (Q Sepharose)
Buffer A: 20mM Tris, pH 8.0
Buffer B: 20mM Tris + 500mM NaCl, pH 8.0
Linear gradient 0-100% B over 20 column volumes
Final buffer exchange into PBS using TFF (tangential flow filtration)
5. Characterization Methods
5.1 Purity Analysis
SDS-PAGE under reducing and non-reducing conditions
SEC-HPLC for aggregate detection (TSKgel G3000SWXL column)
Target purity: >95% monomer
5.2 Identity Confirmation
Peptide mapping by trypsin digestion followed by LC-MS/MS
N-terminal sequencing by Edman degradation
Intact mass analysis by ESI-MS
5.3 Functional Assays
ELISA binding assay to recombinant human sclerostin
SPR (Biacore) for kinetic analysis (KD should be <0.5nM)
Cell-based assay using U2OS cells with sclerostin-induced luciferase reporter
6. Formulation and Storage
6.1 Final Formulation
Concentration: 210mg/mL romosozumab
Buffer: 20mM histidine, pH 5.5
Additives:
5% sucrose (cryoprotectant)
0.02% polysorbate 20 (surfactant)
0.1% L-arginine (stabilizer)
6.2 Sterile Filtration
Filter through 0.22µm PVDF filter into sterile containers
Perform endotoxin testing (LAL assay) - must be <0.5EU
| Parameter | Specification |
| Appearance | Clear, colorless solution |
| pH | 5.5 ±0.2 |
| Concentration | 210±10mg/mL |
| Purity (SEC-HPLC) | >95% monomer |
| Aggregates | <3% |
| Fragments | <2% |
| Endotoxin | <0.5EU/mL |
| Binding activity | 90-110% of reference |
| Sterility | Negative |
If you read till here just jfl and swim a bit to not to think about it im out!
